

## Elements in cancer treatment

Lubinski J.A.<sup>1,2</sup>, Marciniak W.<sup>2</sup>, Derkacz R.<sup>2</sup>, Gronwald J.<sup>1</sup>, Cybulski C.<sup>1</sup>, Huzarski T.<sup>1</sup>, Dębniak T.<sup>1</sup>, Lubiński J.<sup>3</sup>, Lener M.<sup>1</sup>, Jakubowska A.<sup>1</sup>, Szwiec M.<sup>4</sup>, Pietrzak S.<sup>1</sup>, Baszuk P.<sup>1</sup>, Rogoża-Janiszewska E.<sup>1</sup>, Białkowska K.<sup>1</sup>, Rudnicka H.<sup>1</sup>, Rowińska K.<sup>1</sup>, Falco M.<sup>5</sup>, Wójcik J.<sup>6</sup>, Grodzki T.<sup>5</sup>, Sun P.<sup>7</sup>, Scott R.J.<sup>8</sup>, Narod S.A.<sup>9,10</sup>.

<sup>1</sup>Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland

<sup>2</sup>Read-Gene, Grzeczka, ul. Alabastrowa 8, 72-003 Dobra (Szczecińska), Poland

<sup>3</sup>Clinic of Otolaryngology and Laryngological Oncology, Pomeranian Medical University, Unii Lubelskiej 1, 71-252 Szczecin, Poland.

<sup>4</sup>Department of Surgery and Oncology, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland.

<sup>5</sup>Regional Oncology Centre, 71-730 Szczecin, Poland

<sup>6</sup>Department of Thoracic Surgery and Transplantation, Pomeranian Medical University, ul. A. Sokołowskiego 11, 70-891, Szczecin, Poland

<sup>7</sup>Women's College Research Institute, 76 Grenville Street, 6th Floor, Toronto, ON, M5S 1B2, Canada.

<sup>8</sup>Medical Genetics, Hunter Medical Research Institute; Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle; Pathology North, John Hunter Hospital, Cnr King and Auckland Streets, Newcastle, NSW, 2300, Australia.

<sup>9</sup>Women's College Research Institute, 76 Grenville Street, 6th Floor, Toronto, ON, M5S 1B2, Canada.

<sup>10</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

## Abstract

During the last few years we performed series of studies on correlation between serum levels of panel of elements – As, Se, Zn, Cu, Mn, Cd and Pb, and survival in malignant tumours of various sites: cancers of the breast, prostate, lung, larynx, pancreas and malignant melanoma. Except of clinically advanced cancers of the lung and pancreas (stages II-IV) in all other malignancies there were found unequivocal (statistically significant or strong tendencies) correlations between serum Se, Zn, and Cu levels and patients 5 and/or 10 years survivals. Interestingly, optimal levels of elements were similar in different tumours: Se - ~100µg/l, Zn - ~1100 µg/l and Cu - ~900µg/l.